… combination of monalizumab and cetuximab in patients with R/… However, there are no data
of single-agent monalizumab in … study evaluating monalizumab monotherapy in R/M SCCHN. …

… The multicenter phase II trial tested the combination of monalizumab and cetuximab in pts
with R/M SCCHN. Pts received monalizumab 10 mg/kg q2weeks and cetuximab according to …

… Monalizumab (mona) is a human IgG4 antibody targeting the NKG2A receptor. … Monalizumab
(mona) is a human IgG4 antibody targeting the NKG2A receptor. Methods The UPSTREAM …

Background: Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A receptors
expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A ligand, …

… Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group … of monalizumab
and cetuximab with the addition of durvalumab (cohort 3) in first-line treatment of patients …

… ) with 40 patients planned in each cohort. All patients received monalizumab intravenously
750 … Here we present updated analysis for Cohort 2 and an exploratory analysis of all patients …

… Our results suggest that HLA-E surface expression is a tumor biomarker for monalizumab
efficacy and that the use of monalizumab in combination with other cancer therapies that …

… 2 study, monalizumab (… monalizumab + cetuximab in pts with R/M HNSCC previously treated
with CT and an ICI. Methods: Approximately 624 pts will be randomized 2:1 to monalizumab …

Background First-line (1L) treatment for R/M HNSCC includes ICI+/-CT or CT+ CTX. Treatment
after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ CTX may …

… monalizumab, an ICI targeting NKG2A receptor ( Table 1 ). Results from the INTERLINK-1
trial, a double-blind, placebo-controlled phase III RCT, comparing monalizumab… monalizumab …